Spinal Cord Stimulation for Children With Cerebral Palsy
Martin Piazza · NCT07516067
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 5–17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- March 30, 2026
- Record last updated
- April 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to help understand spinal cord excitability in children with cerebral palsy compared to neurologically typical children. The main questions it aims to answer are:
- What are the mechanisms of spinal circuit hyperexcitability in CP?
- Can transcutaneous spinal cord stimulation reduce spinal circuit hyperexcitability?
Participants with cerebral palsy will be asked to complete:
- Movement and strength exercises
- Mild, non-invasive stimulation on the back and legs that feels like a light tap.
- Gentle, non-invasive tests that help us see how the brain and the spinal cord communicate with the muscles
Being studied: Transcutaneous Spinal Cord Stimulation (tSCS)
Conditions: Cerebral Palsy; Spasticity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
A. Patient-Participant Group (Children with Cerebral Palsy)
- Children aged 5 to 17 years with a confirmed diagnosis of cerebral palsy.
- Gross Motor Function Classification System (GMFCS) Levels I to IV, able to walk with or without assistance (walker or cane). This classification will have been completed by Dr. Martin Piazza and his Movement Disorders clinic team.
- Stable medical condition without recent surgeries or interventions that could affect motor function.
- Must be able to communicate basic needs and follow simple instructions.
- Provision of informed consent by a parent or legal guardian, with assent from the child as appropriate.
B. Control Group (Children without Neurological Diagnoses)
- Children aged 5 to 17 years with no history of neurological diagnoses.
- Must be fully ambulatory without assistance.
- Must be able to communicate basic needs and follow simple instructions.
- Provision of informed consent by a parent or legal guardian, with assent from the child as appropriate.
Exclusion Criteria
- Presence of implanted medical devices (e.g., baclofen pumps, deep brain stimulators) that may interfere with TSCS.
- Severe scoliosis or spinal deformities that could affect the delivery of tSCS.
- Uncontrolled epilepsy or a history of frequent seizures.
- Severe cognitive impairments limiting the ability to comply with study procedures.
- Skin conditions or open wounds at the site of stimulation.
- Participation in other interventional studies that may confound results.
- Any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, etc.) that could affect ability to participate in this study.
Recruiting US locations
UPMC Children's Hospital of Pittsburgh
Pittsburgh, PA 15224
Site contact: Bailey McDonald, BS · 412-692-9966 · mcdonaldbm3@upmc.edu
Study contacts (from the official record)
- Bailey McDonald, BS · 412-692-9966 · mcdonaldbm3@upmc.edu
- Martin G Piazza, MD · piazzamg@upmc.edu
Similar studies in Pennsylvania
All healthy volunteers studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Melissa Pugliano-Mauro
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Philadelphia, PA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Novo Nordisk A/S
- Location
- Hershey, PA + 4 other US sites
- Eligibility basics
- Ages 18–64 · Men only